10X Pops on IPO Day, Amgen’s KRAS Drug Tantalizes, & Lilly’s RET Drug Impresses

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Much Ado about Coronavirus and 23andMe Hits the Wall
Lilly’s Half-Measure on Insulin, Illumina’s Up-Market Play, & the Little Deals from SF
MRNA Vaccines Impress, Blueprint Wins First FDA OK, & Calif. Gov. Stares Down Biotech on the Eve of #JPM20
Merck’s Ebola Vaccine Triumph, Weill’s $106M Neurohub & Teva’s Reversal